XNASPMD
Market cap15mUSD
Dec 12, Last price
2.67USD
Name
Psychemedics Corp
Chart & Performance
Profile
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 22,098 -12.45% | 25,240 1.33% | |||||||
Cost of revenue | 25,019 | 26,323 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,921) | (1,083) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 716 | 44 | |||||||
Tax Rate | |||||||||
NOPAT | (3,637) | (1,127) | |||||||
Net income | (4,154) 283.21% | (1,084) 63.01% | |||||||
Dividends | (799) | (1,186) | |||||||
Dividend yield | 4.70% | 4.30% | |||||||
Proceeds from repurchase of equity | (54) | (78) | |||||||
BB yield | 0.32% | 0.28% | |||||||
Debt | |||||||||
Debt current | 2,401 | 1,331 | |||||||
Long-term debt | 2,938 | 5,218 | |||||||
Deferred revenue | (1,188) | ||||||||
Other long-term liabilities | (305) | ||||||||
Net debt | 3,375 | 1,799 | |||||||
Cash flow | |||||||||
Cash from operating activities | (1,480) | 4,890 | |||||||
CAPEX | (157) | (187) | |||||||
Cash from investing activities | (159) | (208) | |||||||
Cash from financing activities | (1,147) | (1,924) | |||||||
FCF | (3,531) | 5,146 | |||||||
Balance | |||||||||
Cash | 1,964 | 4,750 | |||||||
Long term investments | |||||||||
Excess cash | 859 | 3,488 | |||||||
Stockholders' equity | (18,375) | (13,422) | |||||||
Invested Capital | 28,393 | 25,503 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 5,740 | 5,626 | |||||||
Price | 2.96 -39.65% | 4.90 -30.13% | |||||||
Market cap | 16,990 -38.43% | 27,594 -29.16% | |||||||
EV | 20,365 | 29,393 | |||||||
EBITDA | (251) | 2,233 | |||||||
EV/EBITDA | 13.16 | ||||||||
Interest | 43 | ||||||||
Interest/NOPBT |